Online inquiry

IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ5388MR)

This product GTTS-WQ5388MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD2 gene. The antibody can be applied in Psoriasis, severe chronic plaque research.

Specifications
Product type	mRNA
Modified bases	5-Methyl-CTP & Pseudo-UTP
5' Cap	Cap 1
Species	Homo sapiens
RefSeq	NM_001328609.2
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	914
UniProt ID	P06729

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5388MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ15062MR	IVTScrip™ mRNA-Anti-KDR, SSS-23(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	SSS-23
GTTS-WQ14444MR	IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	RO4858696-000
GTTS-WQ1741MR	IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	ADCT-301
GTTS-WQ10850MR	IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 1, 2-Thio-UTP, 30 nt-poly(A))	mRNA	M9346A
GTTS-WQ2784MR	IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	AMG-282
GTTS-WQ1950MR	IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 1, 2-Thio-UTP, 30 nt-poly(A))	mRNA	AGS15C
GTTS-WQ1642MR	IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	ACE-910
GTTS-WQ8298MR	IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	HM-12525A

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST